SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mark Bong who wrote (4999)8/10/2001 3:09:54 PM
From: Biomaven  Read Replies (1) of 10280
 
Mark,

<<provisions for renegotiation or SEPR concurrence>> in a SGP munch.

I very much doubt there are any given this wasn't a co-promote type deal but a straight license. Also unlikely to be any antitrust issues given that SGP already has Claritin, which will remain a major brand even after it goes generic.

There may just be too much uncertainty surrounding SGP for a munch to happen now. I agree that we likely won't see Clarinex on the market this year.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News